Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin In Dravet Syndrome; First Sites Activated With A Number Of Additional Rapid-Start Sites Being Activated In The Coming Weeks
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin In Dravet Syndrome; First Sites Activated With A Number Of Additional Rapid-Start Sites Being Activated In The Coming Weeks
Longboard Pharmaceuticals啓動第3階段DEEp SEA研究，評估Bexicaserin在Dravet綜合徵中的應用；首批站點已啓動，並將在未來幾周內啓動多個快速啓動站點。
- First sites activated with a number of additional rapid-start sites being activated in the coming weeks
- 首批站點已啓動，並將在未來幾周啓動更多快速啓動站點
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational drugbexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older.
Longboard Pharmaceuticals, Inc.（納斯達克:LBPH），一家臨床階段的生物製藥公司，致力於開發用於治療神經系統疾病的新型、變革性藥物，今天宣佈已開始進行全球第三階段DEEp SEA研究，評估其研究藥物bexicaserin用於治療特拉維特（Dravet）綜合徵患者中兩歲及以上參與者的癲癇。